Drug Trial Radar · NCT04197687
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Last checked: Nov 19, 2026Latest source record: Dec 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
480
Planned (sponsor's estimate)
Start
Feb 20, 2020
Primary completion
Jan 15, 2025
Study completion Jan 15, 2025
Sponsor
- Lead sponsor
- Academic and Community Cancer Research UnitedAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Dec 13, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim increases the number of white blood cells in the body following chemotherapy for certain types of cancer and is used to alert the immune system. It is not yet known if TPIV100 and sargramostim will work better in treating patients with HER2 positive, stage II-III breast cancer.
Conditions
- Breast Adenocarcinoma
- Stage II Breast Cancer AJCC v6 and v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Stage III Breast Cancer AJCC v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7
Interventions
Multi-epitope HER2 Peptide Vaccine TPIV100Biological
Given ID
PertuzumabBiological
permitted at physician's discretion
Placebo AdministrationOther
Given ID
SargramostimBiological
Given ID
TrastuzumabBiological
therapy are at the discretion of the treating physicians
Trastuzumab EmtansineBiological
at the discretion of the treating physicians.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive disease-free survival (iDFS) between the 2 armsTime frame: From time of randomization to recurrence, invasive breast cancer or death, assessed up to 5 years
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Arizona
Scottsdale, Arizona · Recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
Yuma Regional Medical Center
Yuma, Arizona · Withdrawn
City of Hope Comprehensive Cancer Center
Duarte, California · Withdrawn
UC San Diego Moores Cancer Center
La Jolla, California · Not yet recruiting
Middlesex Hospital
Middletown, Connecticut · Withdrawn
University of Florida Health Science Center - Gainesville
Gainesville, Florida · Recruiting
Mayo Clinic in Florida
Jacksonville, Florida · Recruiting
Cleveland Clinic Florida
West Palm Beach, Florida · Withdrawn
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia · Not yet recruiting
Illinois CancerCare-Peoria
Peoria, Illinois · Withdrawn
Carle Cancer Center NCI Community Oncology Research Program
Urbana, Illinois · Withdrawn
Siouxland Regional Cancer Center
Sioux City, Iowa · Withdrawn
University Medical Center New Orleans
New Orleans, Louisiana · Recruiting
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland · Not yet recruiting
Essentia Health NCI Community Oncology Research Program
Duluth, Minnesota · Withdrawn
Mayo Clinic in Rochester
Rochester, Minnesota · Recruiting
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota · Withdrawn
Washington University School of Medicine
St Louis, Missouri · Withdrawn
University of Nebraska Medical Center
Omaha, Nebraska · Recruiting
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire · Recruiting
FirstHealth of the Carolinas-Moore Regional Hospital
Pinehurst, North Carolina · Recruiting
Guthrie Medical Group PC-Robert Packer Hospital
Sayre, Pennsylvania · Withdrawn
Lexington Medical Center
West Columbia, South Carolina · Withdrawn
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee · Not yet recruiting
Inova Fairfax Hospital
Falls Church, Virginia · Withdrawn
Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin · Not yet recruiting
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin · Withdrawn
Dean Hematology and Oncology Clinic
Madison, Wisconsin · Withdrawn
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.